Skip to main content
SpringerLink
Log in

Prevention of HPV-Associated Diseases in the United States

  • Chapter
  • First Online:
HPV and Cervical Cancer

  • 2104 Accesses

Abstract

The dominant HPV-associated disease is cervical cancer. In the US, 88% of the diagnoses and 92% of the costs pertain to controlling cervical cancer and its screening program. Secondary prevention has worked extremely well at reducing the overall incidence of cervical cancer to 8.3/100,000 women, with only black and Hispanic women having incidences of cervical cancer above the national average at 11.1 and 12.8/100,000 respectively.

Gardasil has market dominance in the US. Gardasil is able to reduce the incidence of cervical cancer at its maximal performance to 14/100,000, while Cervarix is able to reduce the incidence to 9.5/100,000. Gardasil will not lower the population-based cervical cancer incidence rate in the US, but may contribute to a lowering of the rate of abnormal Pap tests, colposcopies and treatments for pre-invasive disease.

Recent data indicates that Gardasil may offer protection to heterosexual men for the prevention of genital warts and to men who have sex with men (MSM) for the prevention of anal dysplasia caused by HPV 6/11. A summary table of the populations and efficacies is presented for all populations studied.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • ACOG Practice Bulletin No. 109 (2009) Cervical cytology screening. American College of Obstetricians and Gynecologists. Obstet Gynecol 114:1409–1420

    Google Scholar 

  • Anttila A, Pukkala E, Söderman B, Kallio M, Nieminen P, Hakama M (1999) Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: recent increase in cervical cancer incidence. Int J Cancer 83(1):59–65

    Article  PubMed  CAS  Google Scholar 

  • Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J (2006) Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl 3): S3/78–S3/89

    Google Scholar 

  • Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, Grunwald U, Bedell L, Anemona A, Dull PM (2010) Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 28(18):3171–3179

    Article  PubMed  CAS  Google Scholar 

  • Backes DM, Bleeker MC, Meijer CJ, Hudgens MG, Agot K, Bailey RC, Ndinya-Achola JO, Hayombe J, Hogewoning CJ, Moses S, Snijders PJ, Smith JS (2011) Male circumcision is associated with a lower prevalence of human papillomavirus-associated penile lesions among Kenyan men. Int J Cancer. doi:10.1002/ijc.26196

  • Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP (2006) Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modeling analyses. PLoS Med 3:e138

    Article  PubMed  Google Scholar 

  • Block SL, Nolan T, Sattler C et al (2006) Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118:2135–2145

    Article  PubMed  Google Scholar 

  • Blomberg K, Forss A, Ternestedt BM, Tishelman C (2009) From ‘silent’ to ‘heard’: professional mediation, manipulation and women’s experiences of their body after an abnormal Pap smear. Soc Sci Med 68(3):479–486

    Article  PubMed  Google Scholar 

  • Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244–265

    Article  PubMed  CAS  Google Scholar 

  • Bosch FX, de Sanjosé S (2003) Chapter 1: human papillomavirus and cervical cancer – burden and assessment of causality. J Natl Cancer Inst Monogr 31:3–13

    Article  PubMed  Google Scholar 

  • Brewster DH, Bhatti LA (2006) Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975–2002. Br J Cancer 95(1):87–90

    Article  PubMed  CAS  Google Scholar 

  • Brisson M, Van de Velde N, Boily MC (2009) Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 12(5–6):343–351

    Article  PubMed  Google Scholar 

  • Brisson M, Van de Velde N, Boily MC (2010) Modeling the incremental impact of vaccinating boys against HPV. Oral presentation 440. In: 26th international papillomavirus conference, Montreal, 3–8 July 2010

    Google Scholar 

  • Brotherton JM, Gold MS, Kemp AS et al (2008) Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 179(6):525–533

    Article  PubMed  Google Scholar 

  • Brown DR, Kjaer SK, Sigurdsson K et al (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 199:926–935

    Article  PubMed  Google Scholar 

  • Campisi P, Hawkes M, Simpson K, Canadian Juvenile Onset Recurrent Respiratory Papillomatosis Working Group (2010) The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. Laryngoscope 120:1233–1245

    PubMed  Google Scholar 

  • Carreon JD, Sherman ME, Guillén D, Solomon D, Herrero R, Jerónimo J, Wacholder S, Rodríguez AC, Morales J, Hutchinson M, Burk RD, Schiffman M (2007) CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 26(4):441–446

    Article  PubMed  Google Scholar 

  • Castellsagué X, Díaz M, de Sanjosé S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98(5):303–315

    Article  PubMed  Google Scholar 

  • Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A (2011) End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 105(1):28–37

    Article  PubMed  Google Scholar 

  • Centers for Disease Control and Prevention (2010a) Youth risk behavior surveillance — United States, 2009. Surveillance summaries. MMWR 59(SS-5):1–142

    Google Scholar 

  • Centers for Disease Control and Prevention (CDC) (2010b) National, state, and local area vaccination coverage among adolescents aged 13–17 years – United States, 2009. Morb Mortal Wkly Rep 59(32):1018–1023

    Google Scholar 

  • Charo RA (2007) Politics, parents, and prophylaxis–mandating HPV vaccination in the United States. N Engl J Med 356(19):1905–1908

    Article  PubMed  CAS  Google Scholar 

  • Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA (2009) Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 101(16):1120–1130

    Article  PubMed  Google Scholar 

  • Cohen SM (2009) Multiple evanescent white dot syndrome after vaccination for human papilloma virus and meningococcus. J Pediatr Ophthalmol Strabismus 25:1–3

    Google Scholar 

  • Colquhoun P, Nogueras JJ, Dipasquale B, Petras R, Wexner SD, Woodhouse S (2003) Interobserver and intraobserver bias exists in the interpretation of anal dysplasia. Dis Colon Rectum 46(10):1332–1336, discussion 1336–1338

    Article  PubMed  Google Scholar 

  • Committee on Adolescence (2008) Achieving quality health services for adolescences. Pediatrics 121:1263–1270

    Article  Google Scholar 

  • Cooper LZ, Larson HJ, Katz SL (2008) Protecting public trust in immunization. Pediatrics 122(1):149–153

    Article  PubMed  Google Scholar 

  • Cubie HA, Plumstead M, Zhang W, de Jesus O, Duncan LA, Stanley MA (1998) Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11–13-year-old schoolgirls. J Med Virol 56(3):210–216

    Article  PubMed  CAS  Google Scholar 

  • Cuschieri K (2009) Should boys receive the human papillomavirus vaccine? No. BMJ 339:b4921

    Article  PubMed  Google Scholar 

  • Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, Ho L, Terry G, Sasieni P, Dina R, Soutter WP (2008) Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study. Int J Cancer 122(10):2294–2300

    Article  PubMed  CAS  Google Scholar 

  • Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, Cunningham ML, Haupt RM (2009) Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 114(6):1170–1178

    Article  PubMed  Google Scholar 

  • Darragh TM, Winkler B (2011) Anal cancer and cervical cancer screening: key differences. Cancer Cytopathol 119(1):5–19. doi:10.1002/cncy.20126

    Article  PubMed  Google Scholar 

  • Das A, Chang D, Biankin AV, Merrett ND (2008) Pancreatitis following human papillomavirus vaccination. Med J Aust 189(3):178

    PubMed  Google Scholar 

  • de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7(7):453–459

    Article  PubMed  Google Scholar 

  • Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G (2009) Safety of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 5:332–340

    Article  PubMed  Google Scholar 

  • Devaraj B, Cosman BC (2006) Expectant management of anal squamous dysplasia in patients with HIV. Dis Colon Rectum 49:36–40

    Article  PubMed  Google Scholar 

  • De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124(7):1626–1636

    Article  PubMed  CAS  Google Scholar 

  • Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R (2010) Four-year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341:c3493. doi:10.1136/bmj.c3493

    Article  PubMed  Google Scholar 

  • DiMario FJ Jr, Hajjar M, Ciesielski T (2010) A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol 25(3):321–327

    Article  PubMed  Google Scholar 

  • Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK (2011) Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 11(1):39–44

    Article  PubMed  Google Scholar 

  • Dorn HF, Cutler SJ (1955) Morbidity from cancer in the United States. I. Variation in incidence by age, sex, race, marital status, and geographic region. Public Health Monogr 29:1–121

    PubMed  CAS  Google Scholar 

  • Downs TJ, Larson HJ (2007) Achieving millennium development goals for health: building understanding, trust and capacity to respond. Health Policy 83(2–3):144–161

    Article  PubMed  Google Scholar 

  • Dunne EF, Karem KL, Sternberg MR, Stone KM, Unger ER, Reeves WC, Markowitz LE (2005) Seroprevalence of human papillomavirus type 16 in children. J Infect Dis 191(11):1817–1819

    Article  PubMed  Google Scholar 

  • Eggleston KS, Coker AL, Das IP, Cordray ST, Luchok KJ (2007) Understanding barriers for adherence to follow-up care for abnormal Pap tests. J Womens Health 16:311–330

    Article  Google Scholar 

  • Euler GL, Lu P, Singleton JA. CDC/NCIRD revised 2008. http://www.cdc.gov/vaccines/stats-surv/nis/downloads/nis-adult-summer-2007.pdf. Accessed 15 June 2011

  • Eversole GM, Moriarty AT, Schwartz MR et al (2010) Practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med 134:331–335

    PubMed  Google Scholar 

  • Fox PA (2006) Human papillomavirus and anal intraepithelial neoplasia. Curr Opin Infect Dis 19(1):62–66

    Article  PubMed  Google Scholar 

  • Gardasil [package insert] (2009) Merck & Co., Inc., Whitehouse Station

    Google Scholar 

  • Gardner JW, Lyon JL (1977) Efficacy of cervical cytologic screening in the control of cervical cancer. Prev Med 6(4):487–499

    Article  PubMed  CAS  Google Scholar 

  • Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928–1943

    Article  PubMed  CAS  Google Scholar 

  • Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, Saah A, Marino D, Ryan D, Radley D, Zhou H, Haupt RM, Garner EI, Quadrivalent Human Papillomavirus Vaccine Phase III Investigators (2009) Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 114:1179–1188

    Article  PubMed  Google Scholar 

  • Gee J, Naleway A, Shui I, Slade B (2010) Post-licensure safety monitoring of human papillomavirus (HPV) vaccines. ACIP. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct10/08-2-hpv-VaccSafety.pdf. Accessed 15 June 2011

  • Gillison ML, Broutian T, Pickard RKLO, Tong Z, Xiao W, Kahle L, Graubard BI, Chaturvedi AK. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;207(7). doi:10.1001/jama.2012.101

    Article  PubMed  CAS  Google Scholar 

  • Giuliano AR, Lu B, Nielson CM et al (2008) Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 198:827–835

    Article  PubMed  Google Scholar 

  • Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D (2011a) Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364(5):401–411

    Article  PubMed  CAS  Google Scholar 

  • Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, Smith D (2011b) Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 377(9769):932–940

    Article  PubMed  Google Scholar 

  • González P, Hildesheim A, Rodríguez AC, Schiffman M, Porras C, Wacholder S, Piñeres AG, Pinto LA, Burk RD, Herrero R (2010) Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev 19(12):3044–3054

    Article  PubMed  Google Scholar 

  • Gunnell AS, Ylitalo N, Sandin S, Sparén P, Adami HO, Ripatti S (2007) A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev 16(12):2641–2648

    Article  PubMed  Google Scholar 

  • Harper DM (2009a) Primary prevention of HPV-associated diseases. Public Health Genomics 12:319–330

    Article  PubMed  Google Scholar 

  • Harper DM (2009b) Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 8(12):1663–1679

    Article  PubMed  CAS  Google Scholar 

  • Harper DM, Nieminen P, Paavonen J, Lehtinen M (2010a) Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis 10(9):594–595

    Article  PubMed  Google Scholar 

  • Harper DM, Williams KB (2010b) Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med 10(50):7–17

    PubMed  Google Scholar 

  • Harper DM (2011) HPV vaccine against HPV infection and disease in males. N Engl J Med 364(22):2164

    PubMed  CAS  Google Scholar 

  • Harper DM, Vierthaler SL. Who should be targeted for vaccination against anal cancer? Lancet Oncol. 2011 Sep;12(9):828-829. Epub 2011 Aug 22

    PubMed  CAS  Google Scholar 

  • Haupt RM (2010) Gardasil update: Men Protocol 020. ACIP. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct10/08-4-hpv-MaleTrails.pdf. Accessed 15 June 2011

  • Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, Lehtinen MO, Steben M, Joura EA, Giacoletti KE, Radley DR, James MK, Saah AJ, Sings HL, for the FUTURE I and II Investigators (2011) Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer. doi:10.1002/ijc.25940

  • Herbert A, Anshu, Culora G et al (2010) Invasive cervical cancer audit: why cancers developed in a high-risk population with an organised screening programme. BJOG 117(6):736–745

    Article  PubMed  CAS  Google Scholar 

  • Herrero R, Castellsagué X, Pawlita M et al (2003) Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95:1772–1783

    Article  PubMed  Google Scholar 

  • Hibbitts S (2009) Should boys receive the human papillomavirus vaccine? Yes. BMJ 339:b4928

    Article  PubMed  Google Scholar 

  • Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR, Costa Rican HPV Vaccine Trial Group (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccines among young women with preexisting infection: a randomized trial. JAMA 298(7):743–753

    Article  PubMed  CAS  Google Scholar 

  • Hoots BE, Palefsky JM, Pimenta JM, Smith JS (2009) Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 124(10):2375–2383

    Article  PubMed  CAS  Google Scholar 

  • httpa: http://whqlibdoc.who.int/aide-memoire/a87773_eng.pdf, Accessed 15 June 2011

  • httpb: http://www.medscape.com/viewarticle/711461. Accessed 15 June 2011

  • httpc: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237941.htm, 2010. Accessed 15 June 2011

  • httpd: http://www.medscape.com/viewarticle/559807. Accessed 15 June 2011

  • httpe: http://voices.washingtonpost.com/virginiapolitics/2011/02/a_senate_committee_has_killed.html. Accessed 15 June 2011

  • httpf: http://vaers.hhs.gov/data/data/. Accessed 15 June 2011

  • httpg: http://clinicaltrials.gov/. Accessed 15 June 2011

  • httph: http://www.dutchnews.nl/news/archives/2011/05/cervical_cancer_tests_should_i.php. Accessed 15 June 2011

  • Insinga RP, Glass AG, Rush BB (2004) Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 191(1):105–113

    Article  PubMed  Google Scholar 

  • Insinga RP, Liaw KL, Johnson LG, Madeleine MM (2008) A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 17(7):1611–1622

    Article  PubMed  CAS  Google Scholar 

  • IOM (Institute of Medicine) (2011) Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academies Press

    Article  PubMed  CAS  Google Scholar 

  • Jit M, Choi YH, Edmunds WJ (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337:a769

    Article  PubMed  Google Scholar 

  • Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574):1693–1702

    Article  PubMed  CAS  Google Scholar 

  • Kalliala I, Anttila A, Pukkala E, Nieminen P (2005) Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ 331(7526):1183–1185

    Article  PubMed  Google Scholar 

  • Kalliala I, Dyba T, Nieminen P, Hakulinen T, Anttila A (2010) Mortality in a long-term follow-up after treatment of CIN. Int J Cancer 126(1):224–231

    Article  PubMed  CAS  Google Scholar 

  • Kashima HK, Shah F, Lyles A et al (1992) A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 102:9–13

    PubMed  CAS  Google Scholar 

  • Katoulis AC, Liakou A, Bozi E et al (2010) Erythema multiforme following vaccination for human papillomavirus. Dermatology 220:60–62

    Article  PubMed  CAS  Google Scholar 

  • Kessler II (1974) Cervical cancer epidemiology in historical perspective. J Reprod Med 12(5):173–185

    PubMed  CAS  Google Scholar 

  • Khalifa YM, Monahan PM, Acharya NR (2010) Ampiginous choroiditis following quadrivalent human papilloma virus vaccine. Br J Ophthalmol 94(1):137–139

    Article  PubMed  CAS  Google Scholar 

  • Kim JJ, Andres-Beck B, Goldie SJ (2007) The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 97(9):1322–1328

    Article  PubMed  CAS  Google Scholar 

  • Kim JJ, Goldie SJ (2009) Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339:b3884

    Article  PubMed  Google Scholar 

  • Kim JJ (2010) Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 10(12):845–852

    Article  PubMed  Google Scholar 

  • Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, Bailey A, Turner A, Moss S, Peto J (2009) HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 10(7):672–682

    Article  PubMed  Google Scholar 

  • Koppe DC, Bandeira CB, Rosa MR, Cambruzzi E, Meurer L, Fagundes RB (2011) Prevalence of anal intraepithelial neoplasia in women with genital neoplasia. Dis Colon Rectum 54(4):442–445

    Article  PubMed  Google Scholar 

  • Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, Money D, Dionne M, Karunakaran KP, Palefsky JM, Dobson S, Ogilvie G, Petric M (2011) Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 18(3):418–423

    Article  PubMed  CAS  Google Scholar 

  • Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al (2011) CVT Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 103(19):1444–1451

    Google Scholar 

  • Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E (2006) Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367(9509):489–498

    Article  PubMed  CAS  Google Scholar 

  • Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, Stücker M, et al (2010) German Competence Network HIV/AIDS. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol. 162(6):1269–1277. doi:10.1111/j.1365-2133.2010.09712.x

    Google Scholar 

  • Koutsky LA, for the FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915–1927

    Article  Google Scholar 

  • Larson DA, Derkay CS (2010) Epidemiology of recurrent respiratory papillomatosis. APMIS 118:450–454

    Article  PubMed  Google Scholar 

  • Larson HJ, Brocard P, Garnett G (2010) The India HPV-vaccine suspension. Lancet 376(9741):572–573

    Article  PubMed  Google Scholar 

  • Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G (2009) Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 27(2):127–147

    Article  PubMed  Google Scholar 

  • Marsee DK, Williams JM, Velazquez EF (2008) Aluminum granuloma after administration of the quadrivalent human papillomavirus vaccine. Report of a case. Am J Dermatopathol 30(6):622–624

    Article  PubMed  Google Scholar 

  • Marur S, D’Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781–789

    Article  PubMed  Google Scholar 

  • Mayrand MH, Duarte-Franco E, Rodrigues I, Canadian Cervical Cancer Screening Trial Study Group et al (2007) Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357(16):1579–1588

    Article  PubMed  CAS  Google Scholar 

  • McCarthy JE, Filiano J (2009) Opsoclonusmyoclonus after human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord 15(10):792–794

    Article  PubMed  Google Scholar 

  • McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC (2008) Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9(5):425–434

    Article  PubMed  Google Scholar 

  • McCune-Smith K, Sawaya G (2009) Update on quadrivalent human papillomavirus vaccination and pregnancy outcomes: is contraception advisable? Obstet Gynecol 114:1168–1169

    Article  Google Scholar 

  • McGrogan A, Madle GC, Seaman HE, de Vries CS (2009) The epidemiology of Guillain–Barre syndrome worldwide. A systematic literature review. Neuroepidemiology 32(2):150–163

    Article  PubMed  Google Scholar 

  • Muñoz N, Castellsagué X, de González AB, Gissmann L (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine 24(Suppl 3):S3/1–S3/10

    Google Scholar 

  • Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomized, double-blind trial. Lancet 373(9679):1949–1957

    Article  PubMed  CAS  Google Scholar 

  • Muñoz N, Kjaer SK, Sigurdsson K et al (2010) Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 102(5):325–339

    Article  PubMed  CAS  Google Scholar 

  • National Conference of State Legislatures (NCSL). http://www.ncsl.org/default.aspx?tabid=14381#2011. Accessed 15 June 2011

  • Neuzil KM, Canh do G, Thiem VD, Janmohamed A, Huong VM, Tang Y, Diep NT, Tsu V, LaMontagne DS (2011) Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized non-inferiority trial. JAMA 305(14):1424–1431

    Article  PubMed  CAS  Google Scholar 

  • Nielsen A, Munk C, Kjaer SK (2011) Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer. doi:10.1002/ijc.26115

  • Olsson SE, Villa LL, Costa RL et al (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25:4931–4939

    Article  PubMed  CAS  Google Scholar 

  • Olsson SE, Paavonen J (2009a) Impact of HPV 6/11/16/18 vaccine on abnormal Pap tests and procedures. Oral presentation O-01.08. In: 25th international papillomavirus conference, Malmo, 8–14 May 2009

    Google Scholar 

  • Olsson SE, Kjaer SK, Sigurdsson K et al (2009b) Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 5(10):696–704

    Article  PubMed  CAS  Google Scholar 

  • Ojaimi S et al (2009) Quadrivalent human papillomavirus recombinant vaccine associated lipoatrophy. Vaccine 27(36):4876–4878

    Article  PubMed  CAS  Google Scholar 

  • Opalka D, Lachman CE, MacMullen SA et al (2003) Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10(1):108–115

    PubMed  CAS  Google Scholar 

  • Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301–314

    Article  PubMed  CAS  Google Scholar 

  • Paavonen J, on behalf of the HPV PATRICIA Study Group. Efficacy of HPV 16/18 AS04-adjuvanted vaccine against abnormal cytology, colposcopy, colposcopy referrals and cervical procedures. Presentation # SS 4-1. EuroGin. Monte Carlo, Monaco, 17–20 Feb 2010

    Google Scholar 

  • Pagliusi SR, Teresa Aguado M (2004) Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23(5):569–578

    Article  PubMed  Google Scholar 

  • Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM (1998) High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 12(5):495–503

    Article  PubMed  CAS  Google Scholar 

  • Papanicolaou GN (1928) New cancer diagnosis. In: Proceedings of the third race betterment conference, Battlecreek, Michigan, 2–6 Jan 1928, pp 528–534

    Google Scholar 

  • Papanicolaou GN, Traut HF (1941) The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 42:193–206

    Google Scholar 

  • Peto J, Gilham C, Fletcher O, Matthews FE (2004) The cervical cancer epidemic that screening has prevented in the UK. Lancet 364(9430):249–256

    Article  PubMed  Google Scholar 

  • Poppe W, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D et al Vaccine efficacy with/without evidence of prior HPV-16/18 infection: analysis of PATRICIA, a phase III trial with AS04-adjuvanted HVP 16/18 vaccine. Presented at ESGO poster #115, Belgrade, 11–14 Oct 2009

    Google Scholar 

  • Porras C, Rodríguez AC, Hildesheim A, Herrero R, González P, Wacholder S, Burk RD, Schiffman M (2009) Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev 18(3):863–865

    Article  PubMed  CAS  Google Scholar 

  • Prati M, Mezzetti SM, Robertson C, Sideri M (2000) Inter-observer variation in histopathological diagnosis and grading of vulvar intraepithelial neoplasia: results of an European collaborative study. BJOG 1107:594–599

    Google Scholar 

  • Pugnet G, Ysebaert L, Bagheri H et al (2009) Immune thrombocytopenia purpura following human papillomavirus vaccination. Vaccine 27(28):3690

    Article  PubMed  Google Scholar 

  • Quinn M, Babb P, Jones J, Allen E (1999) Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318:904–908

    Article  PubMed  CAS  Google Scholar 

  • Ramqvist T, Dalianis T (2010) Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis (serial on the Internet) 16(11):1671–1677. http://www.cdc.gov/EID/content/16/11/1671.htm. Accessed 15 June 2011

  • Reisinger KS, Block SL, Collins-Ogle M et al (2010) Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics 125:1142–1151

    Article  PubMed  Google Scholar 

  • Report on Carcinogens (2004) Eleventh edition. http://ntp.niehs.nih.gov/files/11thROC_factsheet_1-31-05.pdf

  • Ries LA, Eisner MP, Kosary CL et al (2002) SEER cancer statistics review, 1973-1999. National Cancer Institute, Bethesda

    Google Scholar 

  • Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillén D, Alfaro M, Morales J, Hutchinson M, Katki H, Cheung L, Wacholder S, Burk RD (2010) Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 102(5):315–324

    Article  PubMed  Google Scholar 

  • Rogstad KE (2002) The psychological impact of abnormal cytology and colposcopy. BJOG 109(4):364–368

    Article  PubMed  CAS  Google Scholar 

  • Rothman SM, Rothman DJ (2009) Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA 302(7):781–786

    Article  PubMed  CAS  Google Scholar 

  • Rowhani-Rahbar A, Mao C, Hughes JP et al (2009) Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 27:5612–5619

    Article  PubMed  CAS  Google Scholar 

  • Safaeian M, Porras C, Schiffman M et al (2010) Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 102(21):1653–1662

    Article  PubMed  CAS  Google Scholar 

  • Santoso JT, Long M, Crigger M, Wan JY, Haefner HK (2010) Anal intraepithelial neoplasia in women with genital intraepithelial neoplasia. Obstet Gynecol 116(3):578–582

    Article  PubMed  Google Scholar 

  • Sasieni P, Castanon A, Cuzick J (2009) Effectiveness of cervical screening with age: population based case–control study of prospectively recorded data. BMJ 339:b2968. doi:10.1136/bmj.b2968

    Article  PubMed  Google Scholar 

  • Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, Cohen C, American Cancer Society (2002) American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52(6):342–362

    Article  PubMed  Google Scholar 

  • Sawaya GF, Grimes DA (1999) New technologies in cervical cytology screening: a word of caution. Obstet Gynecol 94(2):307–310

    Article  PubMed  CAS  Google Scholar 

  • Schiffman M, Kjaer SK (2003) Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31:14–19

    Article  PubMed  Google Scholar 

  • Schiffman M (2007) Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing cancer. Cancer Cytopathol 111:145–153

    Google Scholar 

  • Scholefield JH, Castle MT, Watson NF (2005) Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg 92:1133–1136

    Article  PubMed  CAS  Google Scholar 

  • Sherman ME, Paull G (1993) Vaginal intraepithelial neoplasia. Reproducibility of pathologic diagnosis and correlation of smears and biopsies. Acta Cytol 37(5):699–704

    PubMed  CAS  Google Scholar 

  • Shepherd NA (2007) Anal intraepithelial neoplasia and other neoplastic precursor lesions of the anal canal and perianal region. Gastroenterol Clin North Am 36(4):969–987, ix

    Article  PubMed  Google Scholar 

  • Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103(9):753–762

    Article  PubMed  Google Scholar 

  • Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, Beijers-Broos A, Bulten J, Arbyn M (2009) Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 302(16):1757–1764

    Article  PubMed  CAS  Google Scholar 

  • Slade BA, Gee J, Broder KR, Vellozzi C, Comment on the contribution by Souayah et al (2011) Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006–2009. Vaccine 29(5):865–866

    Article  PubMed  Google Scholar 

  • Smith HO, Tiffany MF, Qualls CR, Key CR (2000) The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States – a 24-year population-based study. Gynecol Oncol 78(2):97–105

    Article  PubMed  CAS  Google Scholar 

  • Souayah N, Michas-Martin PA, Nasar A, Krivitskaya N, Yacoub HA, Khan H, Qureshi AI (2010) Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006–2009. Vaccine 29(5):886–889

    Article  PubMed  Google Scholar 

  • Srodon M, Stoler MH, Baber GB, Kurman RJ (2006) The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 30(12):1513–1518

    Article  PubMed  Google Scholar 

  • Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC (2002) Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186(10):1396–1402

    Article  PubMed  Google Scholar 

  • Strander B, Andersson-Ellström A, Milsom I, Sparén P (2007) Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 335(7629):1077

    Article  PubMed  Google Scholar 

  • Studdiford J, Lamb K, Horvath K et al (2008) Development of unilateral cervical and supraclavicular lymphadenopathy after human papillomavirus vaccination. Pharmacotherapy 28(9):1194–1197

    Article  PubMed  Google Scholar 

  • Sturgis EM, Dahlstrom KR (2009) Inaccurate assumptions about oropharyngeal cancer. BMJ 339:b4525

    Article  PubMed  Google Scholar 

  • Sutcliffe CG, Moss WJ (2010) Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis 10(9):630–642

    Article  PubMed  Google Scholar 

  • Sutton I, Lahoria R, Tan I, Clouston P, Barnett M (2009) CNS demyelination and quadrivalent HPV vaccination. Mult Scler 15(1):116–119

    Article  PubMed  CAS  Google Scholar 

  • Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki FY, Schwarz TF, Bosch FX, Harper DM, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G (2011) For the HPV PATRICIA Study Group. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer. doi: 10.1002/ijc.26362

    Article  PubMed  CAS  Google Scholar 

  • Trottier H, Mahmud S, Prado JC et al (2008) Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 197:1436–1447

    Article  PubMed  Google Scholar 

  • Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, Rohan TE, Villa LL, Franco EL (2010) Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 70(21):8569–8577

    Article  PubMed  CAS  Google Scholar 

  • http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111274.pdf (2008). Accessed 15 June 2011

  • Vaccines and Related Biological Products Advisory, Jeff Roberts, M.D., FDA/CBER/OVRR/DVRPA (2009) Committee meeting slide 27 - http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM183640.pdf. Accessed 15 June 2011

  • www.fda.gov/downloads/AdvisoryCommittees/…/UCM183842.ppt. Accessed 15 June 2011

    Google Scholar 

  • http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/../VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM184997.ppt. Accessed 15 June 2011

    Google Scholar 

  • CBER (2009). http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM190977.pdf. Accessed 15 June 2011

  • http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM190978.pdf. Accessed 15 June 2011

  • http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm216352.htm. Accessed 15 June 2011

  • VRBPAC Briefing Document (2010) BLA found at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM231522.pdf. Accessed 15 June 2011

  • http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM239865.pdf. Accessed 15 June 2011

  • http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM247710.pdf. Accessed 15 June 2011

  • http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM247722.pdf. Accessed 15 June 2011

  • http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM251763.pdf – mid-adult women BLA 2010. Accessed 15 June 2011

  • US Cancer Statistics Working Group (2010) United States Cancer Statistics: 1999–2006 Incidence and Mortality Web-based report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Also found at http://apps.nccd.cdc.gov/uscs/cancersbyraceandethnicity.aspx. Accessed 15 June 2011

  • van de Nieuwenhof HP, van der Avoort IA, de Hullu JA (2008) Review of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol 68(2):131–156

    Article  PubMed  Google Scholar 

  • Varnai AD, Bollmann M, Griefingholt H, Speich N, Schmitt C, Bollmann R, Decker D (2006) HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis. Int J Colorectal Dis 21(2):135–142

    Article  PubMed  CAS  Google Scholar 

  • Verguts MM, Genbrugge E, de Jong FI (2009) Treatment results in adult-onset recurrent respiratory papillomatosis. B-ENT 5:137–141

    PubMed  CAS  Google Scholar 

  • Vesikari T, Van Damme P, Lindblad N et al (2010) An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 29:314–318

    PubMed  Google Scholar 

  • Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6(5):271–278

    Article  PubMed  Google Scholar 

  • Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95(11):1459–1466

    Article  PubMed  CAS  Google Scholar 

  • Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B, Hildesheim A, Rodríguez AC, Solomon D, Herrero R, Schiffman M, CVT group (2010) Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized controlled trials. Br Med J 340:c712

    Article  Google Scholar 

  • Watson AJ, Smith BB, Whitehead MR et al (2006) Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg 76:715–717

    Article  PubMed  Google Scholar 

  • WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) Human papillomavirus and related cancers in world. Summary report 2010. Available at www.who.int/hpvcentre. Accessed 15 June 2011

  • Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C (2009) Acute disseminated encephalomyelitis following vaccination against human papillomavirus. Neurology 72:2132–2133

    Article  PubMed  CAS  Google Scholar 

  • Wilkin T, Lee JY, Lensing SY et al (2010) Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 202(8):1246–1253

    Article  PubMed  Google Scholar 

  • Winer RL, Lee S-K, Hughes JP, Adam DE, Kiviat NB, Koutsky LA (2003) Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157:218–226

    Article  PubMed  Google Scholar 

  • Wingo PA, Cardinez CJ, Landis SJ, Greenlee RT, Ries LAG, Anderson RN, Thun MJ (2003) Long-term trends in cancer mortality in the United States, 1930–1998. Cancer 97(11 Suppl):3133–3275. doi:10.1002/cncr.11380

    Article  PubMed  Google Scholar 

  • Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U (2009) Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 27(37):5133–5141

    Article  PubMed  Google Scholar 

  • zur Hausen H (1976) Condylomata acuminata and human genital cancer. Cancer Res 36(2 pt 2):794

    PubMed  Google Scholar 

  • zur Hausen H (2009) The search for infectious causes of human cancers: where and why (Nobel lecture). Angew Chem Int Ed Engl 48(32):5798–5808

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Missouri Kansas City School of Medicine, Truman Medical Center Lakewood, 7900 Lee’s Summit Road, Kansas City, MO, 64139, USA

    Diane M. Harper M.D., M.P.H., M.S.

Authors
  1. Diane M. Harper M.D., M.P.H., M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diane M. Harper M.D., M.P.H., M.S. .

Editor information

Editors and Affiliations

  1. Centre Hospitalier Princesse Grace, 1, Avenue Pasteur, Monaco, 98012, Monaco

    Franco Borruto

  2. Université Libre de Bruxelles, Brussels, Belgium

    Marc De Ridder

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Harper, D.M. (2012). Prevention of HPV-Associated Diseases in the United States. In: Borruto, F., De Ridder, M. (eds) HPV and Cervical Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1988-4_9

Download citation

Publish with us

Policies and ethics

Search

Navigation